Keyphrases
Adjunctive Therapy
13%
Antipsychotics
66%
Attention Vigilance
6%
Brain Disorders
13%
Cognitive Functioning
15%
Cognitive Subgroups
13%
Current Treatment
8%
Daily Functioning
15%
Defined Daily Dose
13%
Disease Cognition
13%
Disease Severity
13%
Divergent Effects
13%
Double-blind Randomized Clinical Trial
13%
Estrogen
49%
Estrogen Level
13%
Estrogen-like
7%
Evidence-based Recommendations
13%
Female Body
13%
Female-specific
16%
First-episode Psychosis
16%
Gonadal Hormones
13%
High Dose
7%
Hyperprolactinemia
8%
Improved Outcomes
8%
Male Body
13%
Menopause
23%
Meta-analysis
17%
Non-invasive Brain Stimulation
13%
Pharmacological Treatment
13%
Pharmacotherapy
17%
Positive Symptoms
13%
Postmenopausal Women
28%
Prolactin
30%
Prolactin Hormone
13%
Protective Effect
10%
Psychiatrists
13%
Psychosis
15%
Raloxifene
22%
Relapse Risk
7%
Schizophrenia
15%
Schizophrenia Spectrum Disorders
100%
Schizophrenia Treatment
13%
Sex Hormones
6%
Symptom Severity
19%
Testosterone
13%
Tolerability
6%
Transcranial Direct-current Stimulation (tDCS)
13%
Transcranial Magnetic Stimulation
13%
Treatment of Women
13%
Working Memory
16%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
59%
Aripiprazole
5%
Cohort Study
6%
Comorbidity
6%
Contraceptive Agent
5%
Defined Daily Dose
13%
Endocrine Therapy
16%
Estrogen Deficiency
8%
Hyperprolactinemia
16%
Negative Syndrome
6%
Olanzapine
5%
Pharmacotherapy
18%
Placebo
10%
Positive Syndrome
17%
Prolactin
5%
Psychosis
13%
Quetiapine
8%
Raloxifene
41%
Randomized Clinical Trial
15%
Randomized Controlled Trial
8%
Schizoaffective Psychosis
15%
Schizophrenia Spectrum Disorder
81%
Sex Hormone
13%
Side Effect
12%
Symptom
24%
Tolerability
9%
Typical Antipsychotic
39%
Medicine and Dentistry
Aripiprazole
6%
Cohort Analysis
6%
Contraceptive Agent
6%
Disease
6%
Drug Megadose
10%
Drug Therapy
30%
Estrogen Deficiency
8%
Hyperprolactinemia
18%
Mental Health
6%
Meta-Analysis
6%
Placebo
10%
Postmenopause
17%
Premenopause
13%
Prolactin
8%
Quetiapine
6%
Raloxifene
43%
Randomized Clinical Trial
15%
Randomized Controlled Trial
10%
Schizophrenia Spectrum Disorder
81%
Sex Difference
9%
Sex Hormone
10%
Side Effect
13%
Symptom
23%
Treatment of Schizophrenia
13%
Typical Antipsychotic
44%
